Respira
2 known investors
Respira develops inhaled therapeutic products for pulmonary diseases, including a novel dry-powder inhalation device and lead product candidate RT234 for pulmonary arterial hypertension. The company focuses on creating drug-device combination products using advanced particle engineering and formulation technologies.
BiotechDigital HealthHealthtechMedical Devices
Founders & leadership
JK
John KollinsChief Executive Officer
Investors · 2
Competitors · 3
by search overlapRespiramedical13 shared keywordsRespira provided clinical respiratory services, sleep, home medical equipment, and home health care to patients across the Mid-Atlantic Region. The company ceased business operations as of March 9, 2018.
Freespira10 shared keywordsFreespira is a medication-free treatment device that uses breathing regulation training to address panic attacks and PTSD symptoms. The platform combines a breathing sensor, tablet app with real-time feedback, and support from a care specialist to teach users breathing pattern control over a 28-day program.
Spyre Therapeutics9 shared keywordsSpyre Therapeutics is a clinical-stage biotechnology company developing antibody therapies for immunology, aiming for more complete disease control, greater durability, and simpler treatment. Its pipeline targets validated mechanisms to treat gastrointestinal and rheumatic conditions in patients.
Companies competing with Respira for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Respira do?
- Respira develops inhaled therapeutic products for pulmonary diseases, including a novel dry-powder inhalation device and lead product candidate RT234 for pulmonary arterial hypertension. The company focuses on creating drug-device combination products using advanced particle engineering and formulation technologies.
- Who are Respira's investors?
- Respira's investors include Cottonwood Technology Fund, Samsara BioCapital.